Legal & General Group
STRO icon

Legal & General Group’s Sutro Biopharma STRO Stock Holding History

Legal & General Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Buy
+3,462
New +$108K ﹤0.01% 2626
2025
Q2 		– Sell
-707
Closed -$4.6K – 3535
2025
Q1 		$4.6K Hold
707
– – ﹤0.01% 3288
2024
Q4 		$13K Hold
707
– – ﹤0.01% 3186
2024
Q3 		$24.5K Hold
707
– – ﹤0.01% 2968
2024
Q2 		$20.7K Buy
707
+211
+43% +$8.34K ﹤0.01% 3002
2024
Q1 		$28K Hold
496
– – ﹤0.01% 2866
2023
Q4 		$21.3K Hold
496
– – ﹤0.01% 3007
2023
Q3 		$17.2K Sell
496
-83
-14% -$3.62K ﹤0.01% 3096
2023
Q2 		$26.9K Buy
579
+64
+12% +$3.19K ﹤0.01% 2984
2023
Q1 		$23.8K Hold
515
– – ﹤0.01% 3018
2022
Q4 		$41.6K Buy
515
+55
+12% +$3.82K ﹤0.01% 2976
2022
Q3 		$26K Buy
460
+89
+24% +$5.27K ﹤0.01% 3139
2022
Q2 		$19K Sell
371
-756
-67% -$42.2K ﹤0.01% 3260
2022
Q1 		$92K Hold
1,127
– – ﹤0.01% 2889
2021
Q4 		$167K Hold
1,127
– – ﹤0.01% 2783
2021
Q3 		$213K Buy
1,127
+635
+129% +$121K ﹤0.01% 2673
2021
Q2 		$92K Buy
492
+151
+44% +$29.6K ﹤0.01% 2771
2021
Q1 		$78K Buy
341
+27
+9% +$6.41K ﹤0.01% 2688
2020
Q4 		$68K Buy
314
+20
+7% +$3.31K ﹤0.01% 2711
2020
Q3 		$30K Buy
294
+29
+11% +$2.74K ﹤0.01% 2852
2020
Q2 		$21K Buy
265
+125
+89% +$12K ﹤0.01% 3055
2020
Q1 		$14K Sell
140
-50
-26% -$5.25K ﹤0.01% 3055
2019
Q4 		$21K Buy
190
+8
+4% +$825 ﹤0.01% 3171
2019
Q3 		$17K Hold
182
– – ﹤0.01% 3186
2019
Q2 		$21K Buy
182
+83
+84% +$9.15K ﹤0.01% 3179
2019
Q1 		$11K Hold
99
– – ﹤0.01% 3238
2018
Q4 		$9K Buy
+99
New +$11.9K ﹤0.01% 3280

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Legal & General Group's STRO Position: Q2 2026 in Review

Legal & General Group opened a new position in Sutro Biopharma (STRO) in Q2 2026: 3,462 shares worth $115K. The stake represents ﹤0.01% of the portfolio and ranks #2626 among its holdings. This is a return to the name: Legal & General Group previously reported a position in STRO as recently as Q1 2025.

Legal & General Group first reported a position in STRO in Q4 2018 and has held it in 27 quarters since. The position peaked at $213K in Q3 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Legal & General Group held 3,462 shares of Sutro Biopharma worth $115K as of Q2 2026.
  • Sutro Biopharma was a new Legal & General Group position in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2626 holding.
  • Legal & General Group first reported a position in Sutro Biopharma in Q4 2018 and has held it in 27 quarters since.
  • Legal & General Group's Sutro Biopharma position peaked at $213K in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.